Paradigm Biocapital Advisors LP Pliant Therapeutics, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.62 Billion
- Q4 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 3,197,050 shares of PLRX stock, worth $9.85 Million. This represents 1.61% of its overall portfolio holdings.
Number of Shares
3,197,050
Previous 3,104,486
2.98%
Holding current value
$9.85 Million
Previous $34.8 Million
20.99%
% of portfolio
1.61%
Previous 1.25%
Shares
2 transactions
Others Institutions Holding PLRX
# of Institutions
175Shares Held
64.8MCall Options Held
228KPut Options Held
772K-
Deep Track Capital, LP Greenwich, CT5.97MShares$18.4 Million3.46% of portfolio
-
Black Rock Inc. New York, NY4.97MShares$15.3 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.63MShares$14.3 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.23MShares$9.94 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.01MShares$9.28 Million25.76% of portfolio
About PLIANT THERAPEUTICS, INC.
- Ticker PLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,682,000
- Market Cap $150M
- Description
- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...